Johnson & Johnson (NYSE:JNJ) Shares Purchased by Dominguez Wealth Management Solutions Inc.

Posted by Defense World Staff on Sep 24th, 2023

Dominguez Wealth Management Solutions Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,438 shares of the company’s stock after purchasing an additional 159 shares during the quarter. Johnson & Johnson comprises approximately 3.4% of Dominguez Wealth Management Solutions Inc.’s portfolio, making the stock its 7th largest holding. Dominguez Wealth Management Solutions Inc.’s holdings in Johnson & Johnson were worth $3,879,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Peak Asset Management LLC grew its holdings in shares of Johnson & Johnson by 9.3% during the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after buying an additional 1,171 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Johnson & Johnson by 0.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after purchasing an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after purchasing an additional 161,687 shares in the last quarter. Tekla Capital Management LLC boosted its holdings in Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after purchasing an additional 82,100 shares in the last quarter. Finally, Wisconsin Capital Management LLC boosted its holdings in Johnson & Johnson by 0.8% in the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after purchasing an additional 127 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Activity

In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

Shares of Johnson & Johnson stock opened at $160.50 on Friday. The business has a 50 day moving average price of $166.51 and a 200 day moving average price of $162.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The company has a market capitalization of $417.13 billion, a P/E ratio of 32.49, a P/E/G ratio of 3.27 and a beta of 0.54. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a $1.19 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Credit Suisse Group lifted their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Citigroup assumed coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 18th. Morgan Stanley lowered their price objective on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $170.65.

Get Our Latest Stock Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.